Besides, two phase II clinical trials evaluated the efficacy of LD in combination with trastuzumab and docetaxel as neoadjuvant treatment for patients with HER2-positive BC and reported tpCR rates of 27% (19) and 38.3% (20). Here, ERBB2 is linked to breast cancer.